Z-1436-2021 Class II Terminated

Recalled by Stryker Leibinger GmbH & Co. KG — Freiburg Im Breisgau, N/A

FDA device recall Z-1436-2021 was initiated by Stryker Leibinger GmbH & Co. KG on Apr 1, 2021 and is designated Class II. Reason for recall: Inability for the user to inject the paste from the syringe into the target location. The recall status is terminated (terminated Dec 19, 2022). Affected quantity: 321 units.

Recall details

Product Type
Devices
Report Date
Apr 28, 2021
Initiation Date
Apr 1, 2021
Termination Date
Dec 19, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
321 units

Product description

DirectInject consists of a sterile dual paste system which is calcium phosphate based. Upon injection through the Mixer-Cannula, the two pastes form a cement paste which is moldable. The injected cement paste will harden under normal body conditions to form hydroxyapatite.

Reason for recall

Inability for the user to inject the paste from the syringe into the target location.

Distribution pattern

Worldwide distribution - US Nationwide distribution and the countries of Germany, Italy, France, Australia, Japan.

Code information

Lot: DI20311,DI20307 Product Code (UDI): 07613327123265

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1436-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1436-2021. Report a data issue: hello@regdatalab.com.